Skip to content

Effect of Alpha-lipoic Acid on Biochemical Markers and Important Outcomes in Patients Admitted to Intensive Care Units

Evaluating the Effect of Alpha Lipoic Acid on Biochemical Markers, Length of Stay and Other Important Outcomes in Patients Admitted to Intensive Care Units.

Status
UNKNOWN
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01888861
Enrollment
80
Registered
2013-06-28
Start date
2013-02-28
Completion date
2013-09-30
Last updated
2013-06-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Oxidative Stress, Inflammation, Malnutrition

Keywords

length of stay in ICU, ventilator free days

Brief summary

Increasing Reactive oxygen and nitrogen production occurred simultaneously with decreasing serum and intracellular level of antioxidants and enzymes in critical ill patients, which result in increasing ventilator dependency and length of stay in intensive care unit and it also accelerate organ failures in patients. In this double blind clinical trial, the investigators examine effect of alfa-lipoic acid on those patients who admitted to intensive care unit that the investigators expect to stay for more than 7 days in this ward and who have tube feeding and don't have severe liver and kidney failure, AIDS and hepatitis. After randomization of included patients by block randomization the investigators will give 900mg/day alfa-lipoic acid for ten days to treatment group and identical placebo to control group by naso-gastric tube. The purposes of this study are decreasing ventilator dependency period, length of stay in ICU, mortality and decelerate of organ failures.

Interventions

DIETARY_SUPPLEMENTalpha-lipoic acid

the patients in this arm receive 900mg alpha-lipoic acid through NG tube.

DRUGplacebo

the patients in this arm were received 900mg placebo through NG tube.

Sponsors

Shiraz University of Medical Sciences
CollaboratorOTHER
najmeh hejazi
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
TRIPLE (Subject, Caregiver, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* age ≥ 18; * expected length of stay more than 7 days; * using enteral feeding method during admitted to ICU

Exclusion criteria

* having the history of autoimmune disease * severe renal or liver failure * AIDS, * hepatitis; * having severe malnutrition at the admission time; * having TPN at the admission time in ICU; * extreme intolerance to enteral feeding.

Design outcomes

Primary

MeasureTime frameDescription
length of stay in ICUday 28number of days that patient stay in intensive care unit
mortalityday 28percent of mortality
ventilator free days10 daysshow by days

Secondary

MeasureTime frameDescription
total antioxidant capacity10 daysmeasure by eliza kit
C reactive protein10 daysmeasure by nephelometry method
interleukin-610 daysmeasure by eliza kit
Albumin10 daysrecord from routine lab data of patients in hospital
sequential organ failure assessment score10 daysdetermine by SOFA score form
Total lymphocyte count10 daysrecord from routine lab data of patients in hospital
Mid arm circumference10 daysmeasure by non flexible meter in mid arm
total protein10 daysrecord from routine lab data of patients in hospital
preAlbumin10 daysby turbidimetric assay
insulin resistance10 daysmeasure by HOMA calculation equation
malondialdehyde10 daysmeasure by spectrophotometery

Countries

Iran

Contacts

Primary ContactNajmeh Hejazi, Ph.D
n20hejazi@yahoo.com

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026